Prognostic factors of axillary lymph node-positive patients in clinical stage II and III breast cancer after neoadjuvant chemotherapy

2018 ◽  
Vol 2 ◽  
pp. 37-37
Author(s):  
Shan-Jun Yang ◽  
Chu-Ping Pi ◽  
Tung-Hao Chang ◽  
Mu-Tai Liu ◽  
Chia-Chun Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Axillary Lymph Node ◽  
Clinical Stage ◽  
Stage Ii ◽  
Axillary Lymph ◽  
Node Positive ◽  
Lymph Node Positive

Đánh giá kết quả hóa trị bổ trợ phác đồ 4AC + 4 T trên bệnh nhân ung thư vú giai đoạn II, IIIA hạch nách dương tính tại Bệnh Viện Đa Khoa Tỉnh Hà Tĩnh

2020 ◽  
Author(s):  
Phuong Vo Van
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node ◽  
Stage Ii ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Lymph Node Positive ◽  
Grade 3

Objectives: (1) Evaluate the efficacy of 4AC+4T regimen as adjuvant chemotherapy for stage II, IIIA breast cancer patients with axillary lymph node positive. (2) Describe toxicity of the regimen. Methods: Retrospective and prospective descriptive longitudinal study, in 39 stage II-III breast cancer patients with lymph node positive underwent modified radical mastectomy and axillary lymph node dissection, treated with 4AC + 4T regimen at Ha Tinh General Hospital from January 2013 to June 2019. Results: Overall survival was 83.6%. Disease-free survial was 75.6%. DFS and OS are inversely proportional to tumor size, the number of metastatic lymph nodes, ER and/PR positive have a better prognosis than ER/PR negative, stage II disease have better prognosis than stage IIIA (p<0.05). Toxicities of AC+4T: Leukopenia in 64.1% of patients, with 10,1% was grade 3, 4. Neutropenia in 61.5% of patients, with 7,6% was grade 3, 4. Hypopigmentation in 51.3% of patients, with 7,6% was grade 3, 4. Thrombocytopenia in 17.9% of patients. Transaminase elevation in 43.6% of patients, no seen grade 3, 4. Increased blood creatinine was only recorded at grade 1 at 5.1%. Vomiting and nausea 87%, stomatitis 30.8%, diarrhea 38.4%, muscle pain 87%, peripheral neuropathy 74.4% peripheral edema 38.5%. Conclusion: The 4AC + 4T regimen shows high efficacy and a acceptable toxicity in the treatment of stage II, IIIA breast cancer with axillary lymph node positive.

scholarly journals erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 ◽  
Vol 90 (18) ◽  
pp. 1361-1370 ◽  
Author(s):  
Soonmyung Paik ◽  
John Bryant ◽  
Chanheun Park ◽  
Bernard Fisher ◽  
Elizabeth Tan-Chiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Node Positive ◽  
Lymph Node Positive

scholarly journals Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator

2019 ◽  
Vol 13 ◽  
pp. 117822341982876 ◽  
Author(s):  
María Teresa Martínez ◽  
Sara S Oltra ◽  
María Peña-Chilet ◽  
Elisa Alonso ◽  
Cristina Hernando ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Older Patients ◽  
Young Patients ◽  
Axillary Lymph ◽  
Free Survival ◽  
Node Positive ◽  
Lymph Node Positive

Purpose: Breast cancer (BC) in very young women (BCVY) is more aggressive than in older women. The purpose of this study was to evaluate the relevance of a range of clinico-pathological factors in the prognosis of BCVY patients. Methods: We retrospectively analyzed 258 patients diagnosed with BCVY at our hospital from 1998 to 2014; the control group comprised 101 older patients with BC. We correlated clinicopathological factors, treatments, relapse and exitus with age and with previously published miRNA expression data. Results: We identified some significant differences in risk factors between BCVY and older patients. The age at menarche, number of pregnancies, and age at first pregnancy were lower in the BCVY group and had a greater probability of recurrence and death in all cases. Lymph node-positive patients in the BCVY group are associated with a worse prognosis ( P  = .02), an immunohistochemical HER2+ subtype, and disease relapse ( P  = .03). Moreover, there was a shorter time between diagnosis and first relapse in BCVY patients compared with controls, and they were more likely to die from the disease ( P  = .002). Finally, from our panel of miRNAs deregulated in BC, reduced miR-30c expression was associated with more aggressive BC in very young patients, lower overall survival, and with axillary lymph node metastases. Conclusions: Patient age and axillary lymph node status post-surgery are independent and significant predictors of distant disease-free survival, local recurrence-free survival, and overall survival. The HER2+ subtype and lower miR-30c expression are related to poor prognosis in lymph node-positive young BC patients.

Sign in / Sign up

Export Citation Format

Share Document